Neurological Immunotoxicity from Cancer Treatment
| Autor: | Sarah Flanagan Wesley, Philip L. De Jager, Kiran T. Thakur, Aya Haggiagi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
chimeric antigen receptor T-cell therapies
Paraneoplastic Syndromes QH301-705.5 Immune checkpoint inhibitors T cell T-Lymphocytes Review Bioinformatics Immunotherapy Adoptive Catalysis Biomarkers Pharmacological Inorganic Chemistry Immune system Neoplasms neurotoxicity Biomarkers Tumor Medicine Humans CTLA-4 Antigen Meningitis Aseptic Physical and Theoretical Chemistry Biology (General) Adverse effect Molecular Biology Immune Checkpoint Inhibitors QD1-999 Spectroscopy Receptors Chimeric Antigen business.industry Organic Chemistry Cancer General Medicine medicine.disease Chimeric antigen receptor Computer Science Applications Cancer treatment Chemistry medicine.anatomical_structure Encephalitis immune-related adverse events Immunotherapy business checkpoint inhibitors |
| Zdroj: | International Journal of Molecular Sciences, Vol 22, Iss 6716, p 6716 (2021) International Journal of Molecular Sciences |
| ISSN: | 1661-6596 1422-0067 |
| Popis: | The emergence of immune-based treatments for cancer has led to a growing field dedicated to understanding and managing iatrogenic immunotoxicities that arise from these agents. Immune-related adverse events (irAEs) can develop as isolated events or as toxicities affecting multiple body systems. In particular, this review details the neurological irAEs from immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T cell immunotherapies. The recognition and treatment of neurological irAEs has variable success, depending on the severity and nature of the neurological involvement. Understanding the involved mechanisms, predicting those at higher risk for irAEs, and establishing safety parameters for resuming cancer immunotherapies after irAEs are all important fields of ongoing research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|